Exhibit 99.1 CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance BRISBANE, Calif., July 31, 2024, CareDx, Inc. (Nasdaq: CDNA) — today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights • Reported total revenue of $92.3 million, an increase of 31% year-over-year. • Grew Testing Services volume to 43,700 tests, an increase of 17% year-over-year. • Reported GAAP net loss of $1.4 million, non-GAAP net income of $13.6 million, an ...

CareDx, Inc. (NASDAQ:CDNA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director of Investor Relations John Hanna - President & Chief Executive Officer Abhishek Jain - Chief Financial Officer Alex Johnson - President-Patient & Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mason Carrico - Stephens Operator Good day, everyone, and welcome to today's CareDx, Inc. First Quarter 2024 ...

For the quarter ended March 2024, CareDx (CDNA) reported revenue of $72.05 million, down 6.7% over the same period last year. EPS came in at -$0.03, compared to -$0.11 in the year-ago quarter.The reported revenue represents a surprise of +13.24% over the Zacks Consensus Estimate of $63.63 million. With the consensus EPS estimate being -$0.19, the EPS surprise was +84.21%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

7 Strong Testing Services Revenue Growth in Q1 2024 in millions USD Strong Year-Over-Year Revenue Growth Across Products and Digital Solutions Businesses Products Patient and Digital Solutions Significant Improvement in Adjusted EBITDA Losses in Q1 2024 1.Reported adjusted EBITDA losses; 2.Testing Services revenue associated with revenue cycle management (RCM) initiatives including collections from unpaid claims from test results delivered in prior quarters Revised 2024 Guidance | --- | --- | --- | --- | |- ...

FORM 10-Q CAREDX, INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursu ...

[CareDx Reports First Quarter 2024 Results](index=1&type=section&id=CareDx%20Reports%20First%20Quarter%202024%20Results) [Executive Summary & Highlights](index=1&type=section&id=First%20Quarter%202024%20Highlights) CareDx reported Q1 2024 revenue of $72.0 million, sequential growth in Testing Services, and raised its full-year 2024 guidance **First Quarter 2024 Key Financial Highlights** | Metric | Q1 2024 Value | YoY Change | QoQ Change | | :--- | :--- | :--- | :--- | | Total Revenue | $72.0 million | -7% | +10% | | Testing Services Revenue | $53.8 million | -13% | +15% | | Patient & Digital Solutions Revenue | $9.6 million | +12% | N/A | | Product Revenue | $8.6 million | +25% | N/A | | Non-GAAP Net Loss | $(1.4) million | N/A | N/A | | Non-GAAP Net Loss Per Share | $(0.03) | N/A | N/A | | Adjusted EBITDA Loss | $(1.9) million | N/A | N/A | | Cash, Cash Equivalents, Marketable Securities | ~$216 million | N/A | N/A | - SHORE data presented at ISHLT demonstrated that **HeartCare® multimodal testing outperforms** donor-derived cell-free DNA (dd-cfDNA) testing alone in identifying allograft rejection[4](index=4&type=chunk) - Over 30 oral presentations, posters, and two symposia highlighting CareDx's scientific advancements in heart and lung transplantation were presented at the International Society for Heart and Lung Transplantation (ISHLT)[11](index=11&type=chunk) - Expanded payer coverage by **14 million lives** nationwide[24](index=24&type=chunk) - Total AlloSure® and AlloMap® patient results provided were approximately 42,000, a decrease of 16% year-over-year but an **increase of 6% quarter-over-quarter**, marking the third consecutive quarter of growth[5](index=5&type=chunk)[36](index=36&type=chunk) [Management Commentary](index=1&type=section&id=Management%20Commentary) The CEO highlighted the return to sequential growth in Testing Services and the company's leadership in transplant patient care - CEO John W Hanna stated, 'We set a new baseline in our Testing Services business in the second half of 2023 and are **back to delivering sequential growth** I am pleased with the team's strong performance across all businesses this quarter'[5](index=5&type=chunk) - CareDx is positioned as the leader in transplant patient care, with dedication to serving patients as a catalyst for growth[5](index=5&type=chunk) [First Quarter 2024 Financial Results (GAAP)](index=1&type=section&id=First%20Quarter%202024%20Financial%20Results) The company reported Q1 2024 GAAP revenue of $72.0 million and an improved net loss of $16.7 million amid lower operating expenses [Revenue Performance](index=1&type=section&id=Revenue%20Performance) Q1 2024 total revenue was $72.0 million, with Testing Services showing strong sequential growth and benefiting from RCM initiatives **Revenue Breakdown (Three Months Ended March 31)** | Revenue Type | Q1 2024 (in thousands) | Q1 2023 (in thousands) | YoY Change | | :--- | :--- | :--- | :--- | | Testing Services Revenue | $53,837 | $61,784 | -13% | | Product Revenue | $8,594 | $6,861 | +25% | | Patient and Digital Solutions Revenue | $9,618 | $8,617 | +12% | | **Total Revenue** | **$72,049** | **$77,262** | **-7%** | - Testing Services revenue benefited from continued revenue cycle management initiatives, adding approximately **$3.7 million in revenue** in the first quarter[13](index=13&type=chunk) [Operating Expenses](index=4&type=section&id=Operating%20Expenses) Total GAAP operating expenses decreased by 10% year-over-year to $91.4 million, driven by reductions across key expense categories **GAAP Operating Expenses (Three Months Ended March 31, in thousands)** | Expense Type | Q1 2024 | Q1 2023 | YoY Change | | :--- | :--- | :--- | :--- | | Cost of testing services | $13,632 | $15,296 | -11% | | Cost of product | $5,344 | $4,066 | +31% | | Cost of patient and digital solutions | $6,958 | $6,604 | +5% | | Research and development | $18,711 | $24,357 | -23% | | Sales and marketing | $19,830 | $23,231 | -15% | | General and administrative | $26,911 | $28,032 | -4% | | **Total Operating Expenses** | **$91,386** | **$101,586** | **-10%** | [Net Loss and EPS](index=2&type=section&id=Net%20Loss%20and%20EPS) The company's GAAP net loss improved to $16.7 million, or $0.32 per share, compared to a loss of $23.7 million in the prior year **GAAP Net Loss and EPS (Three Months Ended March 31)** | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net Loss | $(16,659) thousand | $(23,749) thousand | | Basic Net Loss Per Share | $(0.32) | $(0.44) | | Diluted Net Loss Per Share | $(0.32) | $(0.44) | | Weighted-Average Shares (Basic & Diluted) | 51,692,358 | 53,643,216 | [Balance Sheet Highlights](index=5&type=section&id=Balance%20Sheet%20Highlights) The balance sheet shows total assets of $452.4 million and stockholders' equity of $256.2 million as of March 31, 2024 **Balance Sheet Highlights (in thousands)** | Asset/Liability/Equity | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $93,299 | $82,197 | | Marketable securities | $122,622 | $153,221 | | Accounts receivable | $60,149 | $51,061 | | Total current assets | $303,095 | $313,713 | | Total assets | $452,406 | $466,826 | | Total current liabilities | $70,211 | $78,072 | | Total liabilities | $196,181 | $205,498 | | Total stockholders' equity | $256,225 | $261,328 | [Non-GAAP Financial Measures and Reconciliation](index=2&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) CareDx presents non-GAAP measures, which show improved net loss and adjusted EBITDA, to supplement GAAP results and aid analysis [Non-GAAP Definitions](index=2&type=section&id=Non-GAAP%20Definitions) Non-GAAP results exclude items like stock-based compensation and acquisition-related charges to reflect core operating performance - Non-GAAP net loss and per share results exclude impacts of stock-based compensation, changes in estimated fair value of contingent consideration, acquisition-related impairment charges and amortization of purchased intangible assets and related tax effects, costs involved with completing an acquisition, unrealized loss on investments, restructuring charges, and certain other charges[29](index=29&type=chunk) - Adjusted EBITDA is defined as non-GAAP net loss before net interest income, income tax (benefit) expense, depreciation and other expense, net[17](index=17&type=chunk) [Non-GAAP Operating Expenses](index=6&type=section&id=Non-GAAP%20Operating%20Expenses) Total non-GAAP operating expenses were reduced by 15% year-over-year to $52.3 million in Q1 2024 **Non-GAAP Operating Expenses (Three Months Ended March 31, in thousands)** | Expense Type | Q1 2024 | Q1 2023 | YoY Change | | :--- | :--- | :--- | :--- | | Non-GAAP cost of testing services | $12,846 | $14,488 | -11% | | Non-GAAP cost of product | $4,607 | $3,288 | +40% | | Non-GAAP cost of patient and digital solutions | $6,320 | $5,954 | +6% | | Non-GAAP research and development expenses | $16,926 | $22,395 | -24% | | Non-GAAP sales and marketing expenses | $16,145 | $18,899 | -15% | | Non-GAAP general and administrative expenses | $19,229 | $20,455 | -6% | | **Total Non-GAAP Operating Expenses** | **$52,300** | **$61,749** | **-15%** | [Non-GAAP Gross Profit and Margin](index=9&type=section&id=Non-GAAP%20Gross%20Profit%20and%20Gross%20Margin) Non-GAAP gross profit was $48.3 million in Q1 2024, with a non-GAAP gross margin of 67% **Non-GAAP Gross Profit and Margin (Three Months Ended March 31, in thousands, except percentages)** | Metric | Q1 2024 | Q1 2023 | YoY Change | | :--- | :--- | :--- | :--- | | GAAP gross profit | $46,115 | $51,296 | -10% | | Non-GAAP gross profit | $48,276 | $53,532 | -10% | | Non-GAAP gross margin % | 67% | 69% | -2 ppts | [Non-GAAP Net Loss and EPS](index=2&type=section&id=Non-GAAP%20Net%20Loss%20and%20EPS) The non-GAAP net loss significantly improved to $1.4 million, or $0.03 per share, from $5.8 million in the prior year **Non-GAAP Net Loss and EPS (Three Months Ended March 31)** | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Non-GAAP Net Loss | $(1,448) thousand | $(5,818) thousand | | Non-GAAP Basic Net Loss Per Share | $(0.03) | $(0.11) | | Non-GAAP Diluted Net Loss Per Share | $(0.03) | $(0.11) | | Shares used in computing non-GAAP basic/diluted net loss per share | 51,692,358 | 53,643,216 | [Adjusted EBITDA](index=2&type=section&id=Adjusted%20EBITDA) Adjusted EBITDA loss improved to $1.9 million in Q1 2024, a substantial reduction from losses in prior year and quarter **Adjusted EBITDA (Three Months Ended March 31, in thousands)** | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Adjusted EBITDA | $(1,856) | $(6,415) | | Adjusted EBITDA (Q4 2023) | N/A | $(10,300) | | Adjusted EBITDA assuming recognition of paused claims (Q1 2023) | N/A | $2,497 | [Business Overview](index=2&type=section&id=About%20CareDx%20%E2%80%93%20The%20Transplant%20Company) CareDx is a leading precision medicine company providing high-value healthcare solutions for transplant patients and caregivers - CareDx, Inc is a leading precision medicine solutions company focused on clinically differentiated, high-value healthcare solutions for transplant patients and caregivers[15](index=15&type=chunk) - The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey[15](index=15&type=chunk) - CareDx is the leading provider of genomics-based information for transplant patients[15](index=15&type=chunk) [2024 Financial Guidance](index=1&type=section&id=Raises%202024%20Revenue%20Guidance%20to%20%24274%20to%20%24282%20Million) The company raised its full-year 2024 revenue guidance to a range of $274 million to $282 million **Full Year 2024 Revenue Guidance** | Metric | Range | | :--- | :--- | | Full Year 2024 Revenue | $274 million to $282 million | [Forward-Looking Statements Disclaimer](index=2&type=section&id=Forward%20Looking%20Statements) The report contains forward-looking statements regarding financial guidance and strategy, which are subject to risks and uncertainties - The press release includes forward-looking statements concerning CareDx's 2024 revenue, strategic focus, and proposed path to profitability[28](index=28&type=chunk) - These statements are subject to numerous risks and uncertainties, including general economic and market factors, as detailed in SEC filings (Form 10-K for FY2023, Form 10-Q for Q1 2024)[28](index=28&type=chunk) - CareDx expressly disclaims any obligation to update or revise forward-looking statements, except as required by law[28](index=28&type=chunk) [Contact Information](index=12&type=section&id=Media%20Relations) This section provides contact details for media and investor relations inquiries - Media Relations Contact: Anna Czene, 818-731-2203, aczene@caredx.com[22](index=22&type=chunk) - Investor Relations Contact: Greg Chodaczek, investor@caredx.com[35](index=35&type=chunk)

The upcoming report from CareDx (CDNA) is expected to reveal quarterly loss of $0.19 per share, indicating a decline of 72.7% compared to the year-ago period. Analysts forecast revenues of $63.63 million, representing a decrease of 17.7% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to ...

CareDx (CDNA) shares rallied 5.5% in the last trading session to close at $8.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 20.3% loss over the past four weeks.CareDx scored a strong price increase, driven by investors’ optimism surrounding the recent appointment of John W. Hanna as the new President and Chief Executive Officer of the company. Hanna joins CareDx with more than two decades of executive le ...

One stock that might be an intriguing choice for investors right now is CareDx, Inc (CDNA) . This is because this security in the Medical Services space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical Servic ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024. “We're pleased to welcome Bryan to our Board,” said Michael Goldberg, CareDx Board Chairperson. “His financial expertise ...